vTv Therapeutics falls after FDA places clinical hold on its diabetes study

vTv Therapeutics

26/07/2024 23:14

** Shares of drug developer vTv Therapeutics  VTVT.O  fall
~39% to $12.95 after the bell 
    ** Company says the U.S. FDA has placed a clinical hold on
its ongoing late-stage study testing its experimental treatment
for type 1 diabetes
    ** * Clinical hold was placed after a chromatographic signal
was observed during a recent study which assessed how the drug
was absorbed and distributed into the body - VTVT
    ** Chromatography is a technique used to separate and
analyze different components of a substance
    ** FDA requires a single laboratory test to  characterize
this signal before the study can resume - VTVT
    **  No patient had been dosed in the study at the time of
the clinical hold and past clinical studies did not reveal any
clinically concerning safety issues - VTVT  
    ** Up to last close, stock has risen 84.4% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))